DOCSLIB.ORG

Drug Misuse: Opioid Detoxification

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Misuse: Opioid Detoxification Drug misuse : Opioid : detoxification THE NICE GUIDELINE DRUG MISUSE Opioid detoxification National Clinical Practice Guideline Number 52 National Collaborating Centre for Mental Health commissioned by the National Institute for Health & Clinical Excellence published by The British Psychological Society and The Royal College of Psychiatrists © The British Psychological Society & The Royal College of Psychiatrists, 2008 The views presented in this book do not necessarily reflect those of the British Psychological Society, and the publishers are not responsible for any error of omission or fact. The British Psychological Society is a registered charity (no. 229642). All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society. British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library. ISBN-: 978-1-85433-469-5 Printed in Great Britain by Alden Press. Additional material: data CD-ROM created by Pixl8 (www.pixl8.co.uk) developed by National Collaborating Centre for Mental Health Royal College of Psychiatrists’ Research and Training Unit 4th Floor, Standon House 21 Mansell Street London E1 8AA www.nccmh.org.uk commissioned by National Institute for Health and Clinical Excellence MidCity Place, 71 High Holborn London WCIV 6NA www.nice.org.uk published by The British Psychological Society St Andrews House 48 Princess Road East Leicester LE1 7DR www.bps.org.uk and The Royal College of Psychiatrists 17 Belgrave Square London SW1X 8PG www.rcpsych.ac.uk Contents CONTENTS 1. EXECUTIVE SUMMARY 8 1.1 General considerations 9 1.2 Assessment 11 1.3 Pharmacological interventions in opioid detoxification 12 1.4 Opioid detoxification in community, residential, inpatient and prison settings 14 1.5 Specific psychosocial interventions 16 1.6 Research recommendations 17 2. INTRODUCTION 18 2.1 National guidelines 18 2.2 The national opioid detoxification for drug misuse guideline 21 3. INTRODUCTION TO DRUG MISUSE 23 3.1 Drug misuse and opioid dependence 23 3.2 Epidemiology of drug misuse 25 3.3 Aetiology and maintenance of drug misuse 26 3.4 The course of drug misuse 27 3.5 The pharmacology of opioids 28 3.6 The public health impact of drug misuse 28 3.7 Identification and assessment of drug misuse 30 3.8 The aims of the treatment and management of drug misuse 31 3.9 The development of detoxification services 34 3.10 Current care and treatment in the NHS 35 3.11 The experience of drug misuse – personal perspectives 38 3.12 Impact of drug misuse on families and carers 44 3.13 Economic impact of drug misuse 45 4. METHODS USED TO DEVELOP THIS GUIDELINE 47 4.1 Overview 47 4.2 The scope 47 4.3 The Guideline Development Group 48 4.4 Clinical questions 49 4.5 Systematic clinical literature review 51 4.6 Systematic economic literature review 61 4.7 Stakeholder contributions 63 4.8 Validation of this guideline 63 3 Contents 5. ASSESSMENT AND TESTING 64 5.1 Introduction 64 5.2 Clinical assessment in the management of detoxification 64 5.3 Drug testing 67 5.4 Psychometric assessment tools 72 6. PHARMACOLOGICAL AND PHYSICAL INTERVENTIONS IN OPIOID DETOXIFICATION 76 6.1 Introduction 76 6.2 Pharmacological interventions in detoxification 78 6.3 Overall clinical summary of pharmacological interventions in detoxification 120 6.4 Clinical practice recommendations 120 6.5 Ultra-rapid, rapid and accelerated detoxification using opioid antagonists 122 6.6 Clinical practice recommendations 144 6.7 Physical and complementary interventions during detoxification 144 7. PSYCHOSOCIAL INTERVENTIONS IN OPIOID DETOXIFICATION 146 7.1 Introduction 146 7.2 Current practice 147 7.3 Definitions 148 7.4 Outcomes 150 7.5 Databases searched and inclusion/exclusion criteria 150 7.6 Studies considered 150 7.7 Psychosocial interventions in combination with detoxification 156 7.8 Clinical summary 156 7.9 Literature review of health economics evidence 157 7.10 Economic modelling 157 7.11 Clinical practice recommendations 169 8. SETTINGS FOR OPIOID DETOXIFICATION 170 8.1 Introduction 170 8.2 Inpatient and community-based settings 172 8.3 Unassisted/self-detoxification 180 8.4 Prison-based detoxification 182 9. APPENDICES 185 10. GLOSSARY 244 11. REFERENCES 252 12. ABBREVIATIONS 269 4 Guideline development group members GUIDELINE DEVELOPMENT GROUP MEMBERS Dr Clare Gerada (Chair, Guideline Development Group) General Practitioner, Lambeth Primary Care Trust, London Primary Care Lead for Drug Misuse at the Royal College of General Practitioners Mr Stephen Pilling (Facilitator, Guideline Development Group) Joint Director, The National Collaborating Centre for Mental Health Director, Centre for Outcomes, Research and Effectiveness, University College London Consultant Clinical Psychologist and Deputy Head of Psychology Services, Camden and Islington Mental Health and Social Care Trust Mrs Pauline Bissett Chief Executive, Broadway Lodge Mr Neil Connelly Service User Representative, Voluntary Support Worker, Littledale Hall Therapeutic Community, Lancaster Dr Paul Davis Consultant Lead Clinical Psychologist and Head of Psychology for Substance Misuse Services, Camden and Islington Mental Health and Social Care Trust Ms Vivienne Evans Carer Representative Chief Executive, Adfam Dr Emily Finch Addiction Psychiatrist, South London and Maudsley NHS Foundation Trust Clinical Team Lead, National Treatment Agency for Substance Misuse Professor Robert Forrest Consultant in Clinical Chemistry and Toxicology, Sheffield Teaching Hospitals NHS Foundation Trust Dr Eilish Gilvarry Clinical Director, Newcastle Drug and Alcohol Unit, Newcastle upon Tyne Mr David Harding-Price Team Coordinator, Community Mental Health Team, Skegness, Lincolnshire Mr Paul Hawkins Service User Representative Ms Sarah Hopkins Project Manager, The National Collaborating Centre for Mental Health (2006–2007) 5 Guideline development group members Ms Rebecca King Project Manager, The National Collaborating Centre for Mental Health (2005–2006) Mr Ryan Li Research Assistant, The National Collaborating Centre for Mental Health Dr Anne Lingford-Hughes Reader in Biological Psychiatry and Addiction, Academic Unit of Psychiatry, University of Bristol Addiction Psychiatrist, Avon and Wiltshire Mental Health Partnership NHS Trust Dr Nicholas Meader Systematic Reviewer, The National Collaborating Centre for Mental Health Ms Jan Palmer Nurse Consultant, Clinical Substance Misuse Lead, Offender Health Mrs Kay Roberts Pharmacist; Chairman, PharMAG Ms Poonam Sood Research Assistant, The National Collaborating Centre for Mental Health Ms Sarah Stockton Information Scientist, The National Collaborating Centre for Mental Health Dr Clare Taylor Editor, The National Collaborating Centre for Mental Health Mr Loukas Xaplanteris Health Economist, The National Collaborating Centre for Mental Health 6 Acknowledgements ACKNOWLEDGEMENTS The Guideline Development Group for Drug Misuse: Opioid Detoxification and the National Collaborating Centre for Mental Health (NCCMH) review team would like to thank the following people: Those who acted as advisors on specialist topics or have contributed to the process by meeting with the Guideline Development Group: Dr Ed Day, University of Birmingham Professor Michael Gossop, Institute of Psychiatry Dr Kim Wolff, Institute of Psychiatry Editorial assistance Emma Brown 7 Executive summary 1. EXECUTIVE SUMMARY KEY PRIORITIES FOR IMPLEMENTATION The following recommendations have been identified as recommendations for implementation. Providing information, advice and support ● Detoxification should be a readily available treatment option for people who are opioid dependent and have expressed an informed choice to become abstinent. See section 3.7. ● In order to obtain informed consent, staff should give detailed information to service users about detoxification and the associated risks, including: – the physical and psychological aspects of opioid withdrawal, including the duration and intensity of symptoms, and how these may be managed – the use of non-pharmacological approaches to manage or cope with opioid withdrawal symptoms – the loss of opioid tolerance following detoxification, and the ensuing increased risk of overdose and death from illicit drug use that may be potentiated by the use of alcohol or benzodiazepines – the importance of continued support, as well as psychosocial and appropriate phar- macological interventions, to maintain abstinence, treat comorbid mental health problems and reduce the risk of adverse outcomes (including death). See section 3.7. The choice of medication for detoxification ● Methadone or buprenorphine should be offered as the first-line treatment in opioid detoxification. When deciding between these medications, healthcare professionals should take into account: – whether the service user is receiving maintenance treatment with methadone or buprenorphine; if so, opioid detoxification should normally be started with the same medication – the preference of the service user. See section 6.3. Ultra-rapid detoxification ● Ultra-rapid detoxification under general anaesthesia or heavy sedation (where the airway needs to be supported) must not be offered. This is because of the risk of serious adverse events,
Load more

Recommended publications
  • Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A
    1 Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A. Ban By the mid-1990s the pioneering generation in neuropsychopharmacology was fading away. To preserve their legacy the late Oakley Ray (1931-2007), at the time Secretary of the American College of Neuropsychopharmacology (ACNP), generated funds from Solway Pharmaceuticals for the founding of the ACNP-Solway Archives in Neuropsychopharmacology. Ray also arranged for the videotaping of interviews (mainly by their peers) with the pioneers, mostly at annual meetings, to be stored in the archives. Herbert Kleber was interviewed by Andrea Tone, a medical historian at the Annual Meeting of the College held in San Juan, Puerto Rico, on December 7, 2003 (Ban 2011a; Kleber 2011a). The endeavor that was to become known as the “oral history project” is based on 235 videotaped interviews conducted by 66 interviewers with 213 interviewees which, on the basis of their content, were divided and edited into a 10-volume series produced by Thomas A. Ban, in collaboration with nine colleagues who were to become volume editors. One of them, Herbert Kleber, was responsible for the editing of Volume Six, dedicated to Addiction (Kleber 2011b). The series was published by the ACNP with the title “An Oral History of Neuropsychopharmacology Peer Interviews The First Fifty Years” and released at the 50th Anniversary Meeting of the College in 2011 (Ban 2011b). Herbert Daniel Kleber was born January 19, 1934, in Pittsburgh, Pennsylvania. His family’s father’s side was from Vilnius, Lithuania, and the Mother’s side was from Germany. Both families came to the United State during the first decade of the 20th century.
    [Show full text]
  • Detoxification Strategies for Zearalenone Using
    microorganisms Review Detoxification Strategies for Zearalenone Using Microorganisms: A Review 1, 2, 1 1, Nan Wang y, Weiwei Wu y, Jiawen Pan and Miao Long * 1 Key Laboratory of Zoonosis of Liaoning Province, College of Animal Science & Veterinary Medicine, Shenyang Agricultural University, Shenyang 110866, China 2 Institute of Animal Science, Xinjiang Academy of Animal Sciences, Urumqi 830000, China * Correspondence: [email protected] or [email protected] These authors contributed equally to this work. y Received: 21 June 2019; Accepted: 19 July 2019; Published: 21 July 2019 Abstract: Zearalenone (ZEA) is a mycotoxin produced by Fusarium fungi that is commonly found in cereal crops. ZEA has an estrogen-like effect which affects the reproductive function of animals. It also damages the liver and kidneys and reduces immune function which leads to cytotoxicity and immunotoxicity. At present, the detoxification of mycotoxins is mainly accomplished using biological methods. Microbial-based methods involve zearalenone conversion or adsorption, but not all transformation products are nontoxic. In this paper, the non-pathogenic microorganisms which have been found to detoxify ZEA in recent years are summarized. Then, two mechanisms by which ZEA can be detoxified (adsorption and biotransformation) are discussed in more detail. The compounds produced by the subsequent degradation of ZEA and the heterogeneous expression of ZEA-degrading enzymes are also analyzed. The development trends in the use of probiotics as a ZEA detoxification strategy are also evaluated. The overall purpose of this paper is to provide a reliable reference strategy for the biological detoxification of ZEA. Keywords: zearalenone (ZEA); reproductive toxicity; cytotoxicity; immunotoxicity; biological detoxification; probiotics; ZEA biotransformation 1.
    [Show full text]
  • Advances in Opioid Antagonist Treatment for Opioid Addiction
    Advances in Opioid Antagonist Treatment for Opioid Addiction a, a b Walter Ling, MD *, Larissa Mooney, MD , Li-Tzy Wu, ScD KEYWORDS • Addiction treatment • Depot naltrexone • Opioid dependence • Relapse KEY POINTS • The major problem with oral naltrexone is noncompliance. Administration of naltrexone as an intramuscular injection may be less onerous and improve compliance because it occurs only once a month (ie, extended-release depot naltrexone). • To initiate treatment with extended-release depot naltrexone, steps should be taken to ensure that the patient is sufficiently free from physical dependence on opioids (eg, detoxification). • Research on naltrexone in combination with other medications suggests many opportu- nities for studying mixed receptor activities in the treatment of opioid and other drug addictions. PERSPECTIVE ON OPIOID ANTAGONIST TREATMENT FOR ADDICTION Naltrexone, an opioid antagonist derived from the analgesic oxymorphone, was synthesized as EN-1639A by Blumberg and colleagues in 1967. Four years later, in 1971, naltrexone was selected for high-priority development as a treatment for opioid addiction by the Special Action Office for Drug Abuse Prevention, an office created by President Nixon and put under the leadership of Dr Jerome Jaffe. Extinction Model The rationale for the antagonist approach to treating opioid addiction had been advanced by Dr Abraham Wikler a decade earlier, based largely on the extinction model explored in animal behavioral studies. It was believed that by blocking the euphorogenic effects of opioids at the opioid receptors, opiate use would become Disclosures: Dr Ling has served as a consultant to Reckitt Benckiser Pharmaceuticals and to Alkermes, Inc. Dr Mooney and Dr Wu report no relationships with commercial companies with any interest in the article’s subject matters.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Polypharmacy and the Senior Citizen: the Influence of Direct-To-Consumer Advertising
    2021;69:19-25 CLINICAL GETRIATRICS - ORIGINAL INVESTIGATION doi: 10.36150/2499-6564-447 Polypharmacy and the senior citizen: the influence of direct-to-consumer advertising Linda Sperling, DHA, MSN, RN1, Martine B. Fairbanks, Ed.D, MA, BS2 1 College of nursing, University of Phoenix, Arizona, USA; 2 College of doctoral studies, University of Phoenix, Arizona, USA Background. Polypharmacy, or taking five or more medications dai- ly, can lead to poor medication compliance and an increased risk for adverse drug-to-drug interactions that may eventually lead to death. The study was designed to explore the questions of how age, the re- lationship between the physician and patient, and television, radio, magazines and modern electronic technology, such as the Internet, affect patients’ understanding of their medical care. Two main areas addressed in this research study included the pharmaceutical indus- try’s influence on consumer decisions to ask a physician for a particular medication, and the prescribing practices of the physician. Methods. This qualitative phenomenological study began with pre- screening volunteer residents in a nursing home to discover poten- tial participants who met the criteria of using five or more medicines daily. We then interviewed 24 participants who met the criteria, using semi-structured interview questions. Results. Four core themes emerged from this study: professional trust, professional knowledge, communication deficit, and direct-to-consum- Received: April 30, 2020 er advertising. Participants reported trusting their doctors and taking Accepted: November 2, 2020 medications without question, but most knew why they were taking the Correspondence medications. Participants also reported seeing ads for medications, but Linda Sperling DHA, MSN, RN only one reported asking a physician to prescribe the medication.
    [Show full text]
  • Flashbacks and HPPD: a Clinical-Oriented Concise Review
    Isr J Psychiatry Relat Sci - Vol. 51 - No 4 (2014) Flashbacks and HPPD: A Clinical-oriented Concise Review Arturo G. Lerner, MD,1-2 Dmitri Rudinski, MD,1 Oren Bor, MD,1 and Craig Goodman, PhD1 1 Lev Hasharon Mental Health Medical Center, Pardessya, Israel 2 Sackler School Of Medicine, Tel Aviv University, Ramat Aviv, Israel INTRODUCTION ABSTRACT Hallucinogens encompass a group of naturally occurring A unique characteristic of LSD, LSD-like and substances and synthetic substances (1) which may trigger a transient with hallucinogenic properties is the recurrence of some and generally reversible state of intoxication characterized or all the hallucinogenic symptoms which had appeared by perceptual disturbances primarily visual in nature, often during the intoxication after the immediate effects of the referred to as “trips” (2, 3). A unique characteristic of LSD substance had worn off. This recurring syndrome, mainly (lysergic acid diethylamide) and LSD-like substances is the visual, is not clearly understood. The terms Flashback total or partial recurrence of perceptual disturbances which and Hallucinogen Persisting Perception Disorder (HPPD) appeared during previous intoxication and reappeared in have been used interchangeably in the professional the absence of voluntarily or involuntarily recent use (1-3). literature. We have observed at least two different This syndrome is still poorly understood (2, 3). LSD is the recurrent syndromes, the first Flashback Type we refer prototype of synthetic hallucinogenic substances and it is to as HPPD I, a generally short-term, non-distressing, probably the most investigated hallucinogen associated benign and reversible state accompanied by a pleasant with the etiology of this condition.
    [Show full text]
  • Medications to Treat Opioid Use Disorder Research Report
    Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States.
    [Show full text]
  • Novel Algorithms for the Prophylaxis and Management of Alcohol Withdrawal Syndromes–Beyond Benzodiazepines
    Novel Algorithms for the Prophylaxis and Management of Alcohol Withdrawal Syndromes–Beyond Benzodiazepines José R. Maldonado, MD KEYWORDS Alcohol withdrawal Withdrawal prophylaxis Benzodiazepines Anticonvulsant agents Alpha-2 agonists Delirium tremens KEY POINTS Ethanol affects multiple cellular targets and neural networks; and abrupt cessation results in generalized brain hyper excitability, due to unchecked excitation and impaired inhibition. In medically ill, hospitalized subjects, most AWS cases (80%) are relatively mild and un- complicated, requiring only symptomatic management. The incidence of complicated AWS among patients admitted to medical or critical care units, severe enough to require pharmacologic treatment, is between 5% and 20%. Despite their proven usefulness in the management of complicated AWS, the use of BZDP is fraught with potential complications. A systematic literature review revealed that there are pharmacologic alternatives, which are safe and effective in the management of all phases of complicated AWS. BACKGROUND Alcohol use disorders (AUDs) are maladaptive patterns of alcohol consumption mani- fested by symptoms leading to clinically significant impairment or distress.1 Ethanol is the second most commonly abused psychoactive substance (second to caffeine) and AUD is the most serious drug abuse problem in the United States2 and worldwide.3 The lifetime prevalences of Diagnostic and Statistical Manual of Mental Disorders,4thedi- tion, alcohol abuse and dependence were 17.8% and 12.5%, respectively; the total life- time prevalence for any AUD was 30.3%.4 Alcohol consumption-related problems are the Psychosomatic Medicine Service, Emergency Psychiatry Service, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Suite 2317, Stan- ford, CA 94305-5718, USA E-mail address: [email protected] Crit Care Clin 33 (2017) 559–599 http://dx.doi.org/10.1016/j.ccc.2017.03.012 criticalcare.theclinics.com 0749-0704/17/ª 2017 Elsevier Inc.
    [Show full text]
  • Opioid Weaning Guidance Document Primary Care GENERAL CONSIDERATIONS: 1
    Opioid Weaning Guidance Document Primary Care GENERAL CONSIDERATIONS: 1. Determine if the goal is a dose reduction or complete discontinuation of agent(s). 2. Weans should occur gradually to minimize the risk of withdrawal symptoms. Weaning opioids may take 6 months or more depending on the total opioid dose and the individual patient’s response to the opioid wean. There is no need to rush this process as this may only cause more distress for the patient. 3. Optimize non-opioid pain management strategies. This link provides options for non-opioid strategies: https://www.cdc.gov/drugoverdose/pdf/alternative_treatments-a.pdf a. Recommend implementing one non-opioid agent at a time b. Evaluate and discontinue any agents that are ineffective c. Do not exceed maximum recommended doses or combine multiple agents from the same medication class d. Avoid use of benzodiazepines or any sedative hypnotic agents 4. Set expectations and functional goals with patient prior to initiation of the opioid wean. 5. Educate patient on the change in opioid tolerance over time during the opioid wean and risk for overdose if they resume their starting dose or a previously stable higher dose. Discuss/prescribe naloxone to minimize the risk of overdose. 6. Screen for and treat any untreated/under-treated depression. Depression may make the weaning process more challenging. MORPHINE EQUIVALENT DOSE CALCULATOR: 1. Link to calculator: http://www.agencymeddirectors.wa.gov/Calculator/DoseCalculator.htm 2. This calculator can be utilized to determine the current morphine equivalent dose your patient is receiving at baseline. If the goal is for opioid dose reduction, this calculator can also be used to determine your goal “ending” dose.
    [Show full text]
  • HIV and Substance Use October 2016
    HIV and Substance Use October 2016 Fast Facts • Alcohol and other drugs can affect a person’s judgment and increase risk of getting or transmitting HIV. • In people living with HIV, substance use can worsen the overall consequences of HIV. • Social and structural factors make it difficult to prevent HIV among people who use substances. Substance use disorders, which are problematic patterns of using alcohol or another substance, such as crack cocaine, methamphetamine (“meth”), amyl nitrite (“poppers”), prescription opioids, and heroin, are closely associated with HIV and other sexually transmitted diseases. Injection drug use (IDU) can be a direct route of HIV transmission if people share needles, syringes, or other injection materials that are contaminated with HIV. However, drinking alcohol and ingesting, smoking, or inhaling drugs are also associated with increased risk for HIV. These substances alter judgment, which can lead to risky sexual behaviors (e.g., having sex without a condom, having multiple partners) that can make people more likely to get and transmit HIV. In people living with HIV, substance use can hasten disease progression, affect adherence to antiretroviral therapy (HIV medicine), and worsen the overall consequences of HIV. Commonly Used Substances and HIV Risk • Alcohol. Excessive alcohol consumption, notably binge drinking, can be an important risk factor for HIV because it is linked to risky sexual behaviors and, among people living with HIV, can hurt treatment outcomes. • Opioids. Opioids, a class of drugs that reduce pain, include both prescription drugs and heroin. They are associated with HIV risk behaviors such as needle sharing when injected and risky sex, and have been linked to a recent HIV outbreak.
    [Show full text]
  • The Role of Detoxification in the Maintenance of Health Research
    The Role of Detoxification in the have been reported as well (Table 1).2-11 Exposure to environmental toxicants can occur from air Maintenance of Health pollution, food supply, and drinking water, in addition to skin contact. For example, epidemiological studies have identified Research Review associations between symptoms of Parkinson’s disease and prolonged exposure to pesticides through farming or drinking TOXINS, TOXICANTS & TOXIC SUBSTANCES well water; proximity in residence to industrial plants, printing The word "toxin" itself does not describe a specific class of plants, or quarries; or chronic occupational exposure to 12 compounds, but rather something that can cause harm to the manganese, copper, or a combination of lead and iron. While body. More specifically, a toxin or toxic substance is a the mechanisms of these toxic exposures are not known, an chemical or mixture that may injure or present an individual’s ability to excrete toxins has been shown to be a 13,14 unreasonable risk of injury to the health of an exposed major factor in disease susceptibility. organism. The National Cancer Institute defines "toxin" as a poisonous compound made by bacteria, plants, or animals; it Table 1. Clinical Symptoms and Conditions Associated with defines “toxicant” as a poison made by humans or that is put Environmental Toxicity into the environment by human activities.1 Each toxic substance has a defined toxic dose or toxic concentration at Abnormal pregnancy outcomes which it produces its toxic effect. Atherosclerosis Broad mood swings Environmental pollutants (referred to as exogenous toxicants) Cancer present at variable levels in the air, drinking water, and food Chronic fatigue syndrome supply.
    [Show full text]
  • Help Prevent Relapse to Opioid Dependence After Opioid
    For Opioid Dependence HELP REINFORCE YOUR RECOVERY Help prevent relapse to opioid dependence after opioid detoxification with a non-addictive, once-monthly treatment used with counseling.1,2 VIVITROL® is a prescription injectable medicine used to: Prevent relapse to opioid dependence after opioid detox. You must stop taking opioids or other opioid-containing medications before starting VIVITROL. To be effective, VIVITROL must be used with other alcohol or drug recovery programs, such as counseling. It is not known if VIVITROL is safe and effective in children. See important information about possible side effects with VIVITROL treatment throughout this brochure. Read the Brief Summary of Important Facts about VIVITROL on pages 5–6. This information does not take the place of talking with your healthcare provider. BRIEF SUMMARY OF IMPORTANT FACTS ABOUT VIVITROL ARE YOU OR YOUR LOVED ONE READY TO MOVE FORWARD? Opioid addiction is a chronic brain disease defined by an uncontrollable urge to seek and use opioids, like heroin or prescription pain medication. Because addiction changes the way the brain works, most patients need ongoing care in the form of counseling and medication.3 Discuss all benefits and risks of VIVITROL with your healthcare provider and whether VIVITROL may be right for you. Call your healthcare provider for medical advice about any side effects. PRESCRIBING See important information on possible side effects with VIVITROL treatment throughout this brochure. MEDICATION GUIDE Read the Brief Summary of Important Facts about VIVITROL by clicking the button in the top right-hand INFORMATION 2 corner. This information does not take the place of talking with your healthcare provider.
    [Show full text]